Patents by Inventor Stuart Prince

Stuart Prince has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Insulin-like growth factor II (IGF-II) binding factors
    Patent number: 8658423
    Abstract: This invention relates to modified IGF-II binding domains of the Insulin-like Growth Factor 2 Receptor (IGF2R) which have enhanced binding affinity for IGF-II relative to the wild type IGF-II binding domain. Suitable IGF-II binding domains may be modified, for example, by substituting residue E1544 for a non-acidic residue. These modified domains may be useful in the sequestration of Insulin-like Growth Factor II (IGF-II), for example, in the treatment of cancer.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: February 25, 2014
    Assignee: Cancer Research Technology Limited
    Inventors: Andrew Bassim Hassan, Oliver Zaccheo, Stuart Prince
  • INSULIN-LIKE GROWTH FACTOR II (IGF-II) BINDING FACTORS
    Publication number: 20130071366
    Abstract: This invention relates to modified IGF-II binding domains of the Insulin-like Growth Factor 2 Receptor (IGF2R) which have enhanced binding affinity for IGF-II relative to the wild type IGF-II binding domain. Suitable IGF-II binding domains may be modified, for example, by substituting residue E1544 for a non-acidic residue. These modified domains may be useful in the sequestration of Insulin-like Growth Factor II (IGF-II), for example, in the treatment of cancer.
    Type: Application
    Filed: September 14, 2012
    Publication date: March 21, 2013
    Applicant: Cancer Research Technology Limited
    Inventors: Andrew Bassim Hassan, Oliver Zaccheo, Stuart Prince
  • Insulin-like growth factor II (IGF-II) binding factors
    Patent number: 8293875
    Abstract: This invention relates to modified IGF-II binding domains of the Insulin-like Growth Factor 2 Receptor (IGF2R) which have enhanced binding affinity for IGF-II relative to the wild type IGF-II binding domain. Suitable IGF-II binding domains may be modified, for example, by substituting residue E1544 for a non-acidic residue. These modified domains may be useful in the sequestration of Insulin-like Growth Factor II (IGF-II), for example, in the treatment of cancer.
    Type: Grant
    Filed: August 11, 2006
    Date of Patent: October 23, 2012
    Assignee: Cancer Research Technology Limited
    Inventors: Andrew Bassim Hassan, Oliver Zaccheo, Stuart Prince
  • Insulin-Like Growth Factor II (IGF-II) Binding Factors
    Publication number: 20090304651
    Abstract: This invention relates to modified IGF-II binding domains of the Insulin-like Growth Factor 2 Receptor (IGF2R) which have enhanced binding affinity for IGF-II relative to the wild type IGF-II binding domain. Suitable IGF-II binding domains may be modified, for example, by substituting residue E1544 for a non-acidic residue. These modified domains may be useful in the sequestration of Insulin-like Growth Factor II (IGF-II), for example, in the treatment of cancer.
    Type: Application
    Filed: August 11, 2006
    Publication date: December 10, 2009
    Applicant: CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Andrew Bassim Hassan, Oliver Zaccheo, Stuart Prince